| 39.75 -0.91 (-2.24%) | 08-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 48.42 | 1-year : | 56.56 |
| Resists | First : | 41.45 | Second : | 48.42 |
| Pivot price | 39.58 |
|||
| Supports | First : | 39.27 | Second : | 37.93 |
| MAs | MA(5) : | 39.75 | MA(20) : | 39.54 |
| MA(100) : | 40.74  |
MA(250) : | 41.54 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 51.5 | D(3) : | 51.5 |
| RSI | RSI(14): 48.4 | |||
| 52-week | High : | 49.52 | Low : | 35.16 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NUVA ] has closed below upper band by 43.1%. Bollinger Bands are 34.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 39.79 - 39.98 | 39.98 - 40.15 |
| Low: | 39.28 - 39.51 | 39.51 - 39.7 |
| Close: | 39.41 - 39.76 | 39.76 - 40.06 |
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
Tue, 05 Sep 2023
Should You Investigate NuVasive, Inc. (NASDAQ:NUVA) At US$39.75? - Yahoo Finance
Mon, 28 Aug 2023
NuVasive gains stock amid Nasdaq delisting notice for Globus Medical deal (NASDAQ:NUVA) - Seeking Alpha
Thu, 03 Aug 2023
NuVasive reports mixed Q2 results ahead of expected merger with Globus Medical - Mass Device
Thu, 03 Aug 2023
NuVasive (NUVA) Q2 Earnings Meet Estimates, Margins Down - Yahoo Finance
Wed, 02 Aug 2023
NuVasive Announces Second Quarter 2023 Financial Results - PR Newswire
Thu, 20 Jul 2023
Nuvasive/Globus Medical deal spread widens amid report FTC considering lawsuit - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 52 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 104.7 (%) |
| Shares Short | 5,760 (K) |
| Shares Short P.Month | 7,310 (K) |
| EPS | 0.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.02 |
| Profit Margin | 2.3 % |
| Operating Margin | 6.7 % |
| Return on Assets (ttm) | 2.4 % |
| Return on Equity (ttm) | 3.3 % |
| Qtrly Rev. Growth | 2.4 % |
| Gross Profit (p.s.) | 16.5 |
| Sales Per Share | 23.45 |
| EBITDA (p.s.) | 4.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 140 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | 75 |
| PEG Ratio | 1 |
| Price to Book value | 2.33 |
| Price to Sales | 1.69 |
| Price to Cash Flow | 14.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|